Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Miami
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients must have histologically confirmed in-situ or invasive breast carcinoma.
Tis, T1, T2 invasive or non-invasive carcinoma of the breast; lesion less than 4 cm.
Unifocal, multifocal or multicentric breast cancers that can be removed by nipple sparing mastectomy with negative surgical margins.
No extensive intraductal component or patient with distant metastases.
Patients must be \> 18 years of age.
No concomitant or history of nipple discharge or skin involvement.
No prior history of malignancy (less than 5 years prior to study entry), except non-melanomatous skin cancer.
No prior history of radiation to the chest.
No collagenous disease (systemic lupus erythematosis, scleroderma, dermatomyositis)No previous non-hormonal therapy including radiation or chemotherapy for current breast cancer.
No patients with Paget's disease of the nipple.
No patients with co-existing medical conditions with life expectancy \< 2 years.
No pregnant or lactating women.
Eastern Cooperative Oncology Group (ECOG) 0 - 2.
Signed study-specific informed consent form prior to the study entry.
You may not be if
Retroareolar breast cancer lesions within one cm, depth from the skin surface.
Concomitant or history of nipple discharge or skin involvement.
Patient with distant metastases.
Patient with extensive intraductal carcinoma.
Any previously irradiated ipsilateral breast cancer.
Patients with Paget's disease of the nipple.
Patients with collagenous diseases, as systemic lupus erythematosis, scleroderma or dermatomyositis.
Other malignancy, except nonmelanomatous skin cancer, less than 5 years prior to participation in this study.
Patients who are pregnant or lactating due to potential exposure of the fetus to RT and unknown effects of RT to lactating females.
Positive surgical margins following nipple sparing mastectomy.